D
Dennis M. Black
Researcher at University of California, San Francisco
Publications - 289
Citations - 55905
Dennis M. Black is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Osteoporosis & Bone density. The author has an hindex of 101, co-authored 283 publications receiving 52679 citations. Previous affiliations of Dennis M. Black include University of San Francisco & Claude Bernard University Lyon 1.
Papers
More filters
Journal ArticleDOI
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures
Dennis M. Black,Steven R. Cummings,David B. Karpf,Jane A. Cauley,Desmond E. Thompson,Michael C. Nevitt,Douglas C. Bauer,Harry K. Genant,William L. Haskell,Robert Marcus,Susan M. Ott,James C. Torner,Sara A. Quandt,Theodore F. Reiss,Kristine E. Ensrud +14 more
TL;DR: Among women with low bone mass and existing vertebral fractures, alendronate is well tolerated and substantially reduces the frequency of morphometric and clinical vertebra fractures, as well as other clinical fractures.
Journal ArticleDOI
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial
Bruce Ettinger,Dennis M. Black,Bruce H. Mitlak,Ronald Keith Knickerbocker,Thomas Nickelsen,Harry K. Genant,Claus Christiansen,Pierre D. Delmas,Jose R. Zanchetta,J. A. Stakkestad,Claus C. Glüer,Kathryn A. Krueger,Fredric J. Cohen,Stephen Eckert,Kristine E. Ensrud,Louis V. Avioli,Paul Lips,Steven R. Cummings +17 more
TL;DR: The Multiple Outcomes of Raloxifene Evaluation (MORE) study as mentioned in this paper evaluated the effect of raloxion hydrochloride therapy on risk of vertebral and non-vertebral fractures.
Journal ArticleDOI
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis
Dennis M. Black,Pierre D. Delmas,Richard Eastell,Ian R. Reid,Steven Boonen,Jane A. Cauley,Felicia Cosman,Peter L. Lakatos,Ping Chung Leung,Z. Man,Carlos Mautalen,Peter Mesenbrink,Huilin Hu,John Caminis,Karen Tong,Theresa Rosario-Jansen,Joel S. Krasnow,Trisha F. Hue,Deborah E. Sellmeyer,Erik Fink Eriksen,Steven R. Cummings +20 more
TL;DR: Treatment with zoledronic acid reduced the risk of morphometric vertebral fracture by 70% during a 3-year period, as compared with placebo.
Journal ArticleDOI
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.
Steven R. Cummings,Dennis M. Black,Desmond E. Thompson,William B. Applegate,Elizabeth Barrett-Connor,Thomas Musliner,Lisa Palermo,Ronald J. Prineas,Susan M. Rubin,Jean Scott,Thomas M. Vogt,Robert B. Wallace,A. John Yates,Andrea Z. LaCroix +13 more
TL;DR: In women with low BMD but without vertebral fractures, 4 years of alendronate safely increased BMD and decreased the risk of first vertebral deformity.
Journal ArticleDOI
Bone density at various sites for prediction of hip fractures
Steven R. Cummings,Dennis M. Black,Michael C. Nevitt,Warren S. Browner,Jane A. Cauley,Kristine E. Ensrud,Harry K. Genant,L. Palermo,J. Scott,Thomas M. Vogt +9 more
TL;DR: In this article, the femoral neck bone density was measured by dual X-ray absorptiometry is a better predictor of hip fracture than measurements of other bones, including the radius or calcaneus.